Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

palivizumab

A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Synagis
Code name:MEDI 493
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search